Loto Biotech

LOTO Biotech is a private, preclinical-stage biotech company pioneering an AI-driven platform for the design of siRNA therapeutics targeting rare genetic disorders. Founded by internationally recognized scientists, the company aims to silence disease-causing genes with high specificity, initially focusing on autosomal dominant conditions where silencing the mutated allele can restore health. Its mission is driven by a patient-centric approach, seeking to deliver scalable therapeutic solutions for conditions with high unmet need. The company is currently in the platform and candidate discovery phase, positioning itself in the rapidly growing RNA therapeutics space.

Proprietary AI-driven platform for the in silico design and selection of siRNA-based pro-drugs, followed by preclinical validation. Focused on silencing mutated genes in autosomal dominant diseases.

LOTO operates in the competitive RNA therapeutics space, competing directly with established leaders like Alnylam and Arrowhead Pharmaceuticals, as well as numerous other biotechs exploring siRNA and RNAi platforms. Its differentiation hinges on its specific AI-driven design approach and initial focus on autosomal dominant rare diseases.